Bio-Medicine Pharmaceutical Company Resproly Raised ¥50 Million in a Series A Round Funding Led by Huaige Capital

Bio-Medicine Pharmaceutical Company Resproly Raised ¥50 Million in a Series A Round Funding Led by Huaige Capital
Bio-Medicine Pharmaceutical Company Resproly Raised ¥50 Million in a Series A Round Funding Led by Huaige Capital

Bio-medicine pharmaceutical company Resproly raised ¥50 million in a series A round funding by Huaige Capital, Yanghe Capital, Geli Venture Capital and Zhuhai Kindly Medical Devices CO.,LTD. The investment will be used on factory building, clinical trail application and team building.

Resproly is committed to the R&D, sales and manufacturing of inhaled formulation technology and equipment for respiratory diseases. It focuses on diseases with great clinical needs such as Asthma, COPD, diabetes, Parkinson disease.

South Africa Today


Read more at VolaNews